ResearchIn-Press PreviewAIDS/HIVInfectious disease
Open Access |
10.1172/jci.insight.189909
1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia
3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America
Find articles by Maroney, K. in: PubMed | Google Scholar
1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia
3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America
Find articles by Rose, M. in: PubMed | Google Scholar
1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia
3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America
Find articles by Oman, A. in: PubMed | Google Scholar
1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia
3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America
Find articles by
Chopra, A.
in:
PubMed
|
Google Scholar
|
1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia
3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America
Find articles by Hsieh, H. in: PubMed | Google Scholar
1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia
3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America
Find articles by Derza, Z. in: PubMed | Google Scholar
1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia
3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America
Find articles by Waterworth, R. in: PubMed | Google Scholar
1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia
3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America
Find articles by
Brockman, M.
in:
PubMed
|
Google Scholar
|
1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia
3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America
Find articles by
Kalams, S.
in:
PubMed
|
Google Scholar
|
1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia
3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America
Find articles by
Bansal, A.
in:
PubMed
|
Google Scholar
|
1Department of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, United States of America
2Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Australia
3Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada
4Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America
Find articles by
Goepfert, P.
in:
PubMed
|
Google Scholar
|
Published December 18, 2025 - More info
Few HIV-specific epitopes restricted by non-classical HLA-E have been described, and even less is known about the functional profile of responding CD8 T cells (CD8s). This study evaluates the functional characteristics of CD8s targeting the Gag epitope KF11 (KAFSPEVIPMF) restricted by either HLA-E (E-CD8s) or HLA-B57 (B57-CD8s). CD8s from eight people with HIV (PWH) were cocultured with KF11 peptide presented by cell lines expressing HLA-B*57:01, HLA-E*01:01 or E*01:03. CD8 responses were analyzed using scRNA-seq and scTCR-seq. Supernatants were also assessed for soluble protein profiling. HLA-I multimers were developed to identify CD8s restricted by HLA-B57 and/or HLA-E ex vivo. B57-CD8s secreted higher levels of cytotoxic cytokines such as IFNγ, whereas E-CD8s produced more chemotactic cytokines, including RANTES, CXCL10 (IP-10), and IL27, findings which were corroborated through scRNA sequencing. TCR clonotypes stimulated by KF11 were cross-restricted by HLA-B*57 and HLA-E*01/03 as demonstrated by in vitro T cell reporter assays and ex vivo multimer screening. Ex vivo CD8s were singly restricted by HLA-B57 and HLA-E, with dual restriction only observed in PWH with lower viral load. These findings demonstrate that certain HIV-specific CD8s in PWH exhibit dual restriction by HLA-B*57 and HLA-E*01/03, leading to functionally distinct immune responses depending upon the restricting allele(s).